Back to Sites Molepolole CRS Site Number 12702 Address Molepolole Prevention/Treatment Trials CRS Scottish Livingstone Hospital Gaborone-Molepolole Road Molepolole, Botswana IMPAACT Members at this Site Chenesani Bohule Clinical Research Assistant Ayotunde Omoz-Oarhe Co-Investigator Ponego Ponatshego CRS Coordinator Mpho Raesi CRS Coordinator Akeem Salawu CRS Coordinator Gaerolwe Masheto CRS Leader Ayotunde Omoz-Oarhe CRS Leader Gaerolwe Masheto CTU Coordinator Shahin Lockman CTU Principal Investigator Joseph Moeketsi Makhema CTU Principal Investigator Sue A. Welsch DAIDS PO Farida Monggae Data Manager Masego Rankowa Data Manager Rasak Abdullahi Investigator Unoda Chakalisa Investigator Kenneth Maswabi Investigator Sikhulile Moyo Laboratory Manager/Supervisor Lesedi Tirelo Laboratory QA/QC Coordinator Motswedi Anderson Laboratory Technician/Technologist Rufaro L. Mangwarara Pharmacist Tshepho Theodorah Frank Pharmacy Supervisor Urunduruka Mavis Munamava QA/QC Coordinator Tumalano Sekoto Regulatory Coordinator Tebogo Kakhu Staff Tebogo Mokotedi Staff Kelechi Edgar Nnajide Staff Anthony Chibuzor Ogwu Staff Studies at this Site 1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed P1026S: PK in Pregnancy DAIDS Number 10040 Research Area Treatment Study Status Closed to Follow Up P1072: Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (RotaTeqâ„¢) in HIV-1 Infected and Uninfected Children Born to HIV-1 Infected Mothers DAIDS Number 10638 Research Area Complications & Comorbidities Study Status Concluded P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Treatment Study Status Closed to Accrual IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Enrolling IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants DAIDS Number 20735 Research Area Cure Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Complications & Comorbidities Study Status Open to Accrual IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed Pagination Current page 1 Page 2 Next page Next
1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed
P1072: Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (RotaTeqâ„¢) in HIV-1 Infected and Uninfected Children Born to HIV-1 Infected Mothers DAIDS Number 10638 Research Area Complications & Comorbidities Study Status Concluded
P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Treatment Study Status Closed to Accrual
IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants DAIDS Number 20735 Research Area Cure Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings DAIDS Number 38506 Research Area Complications & Comorbidities Study Status Open to Accrual
IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed